Vivos Therapeutics, Inc.
VVOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $15,031 | $13,801 | $16,024 | $16,885 |
| % Growth | 8.9% | -13.9% | -5.1% | – |
| Cost of Goods Sold | $6,012 | $5,530 | $6,005 | $4,281 |
| Gross Profit | $9,019 | $8,271 | $10,019 | $12,604 |
| % Margin | 60% | 59.9% | 62.5% | 74.6% |
| R&D Expenses | $0 | $100 | $200 | $0 |
| G&A Expenses | $17,878 | $22,479 | $29,041 | $25,791 |
| SG&A Expenses | $19,609 | $24,846 | $34,381 | $31,342 |
| Sales & Mktg Exp. | $1,731 | $2,467 | $5,340 | $5,551 |
| Other Operating Expenses | $581 | $621 | $469 | $733 |
| Operating Expenses | $20,190 | $25,567 | $35,050 | $32,075 |
| Operating Income | -$11,171 | -$17,296 | -$25,031 | -$19,471 |
| % Margin | -74.3% | -125.3% | -156.2% | -115.3% |
| Other Income/Exp. Net | $35 | $3,713 | $1,186 | $94 |
| Pre-Tax Income | -$11,136 | -$13,583 | -$23,845 | -$20,288 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,136 | -$13,583 | -$23,845 | -$20,293 |
| % Margin | -74.1% | -98.4% | -148.8% | -120.2% |
| EPS | -2.22 | -11.14 | -25.9 | -23.89 |
| % Growth | 80.1% | 57% | -8.4% | – |
| EPS Diluted | -2.22 | -11.14 | -25.9 | -23.89 |
| Weighted Avg Shares Out | 5,020 | 1,219 | 920 | 849 |
| Weighted Avg Shares Out Dil | 5,020 | 1,219 | 920 | 849 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $89 | $117 |
| Interest Expense | $0 | $0 | $0 | $14 |
| Depreciation & Amortization | $581 | $621 | $669 | $733 |
| EBITDA | -$10,555 | -$16,675 | -$24,362 | -$19,541 |
| % Margin | -70.2% | -120.8% | -152% | -115.7% |